Insights: News Releases Rubicon Biotechnology Enters Exclusive License Agreement With Department of Veteran Affairs
SAN DIEGO (June 8) – Kilpatrick Townsend & Stockton announced today that the Department of Veteran Affairs (VA) and, firm client, Rubicon Biotechnology, LLC have entered into an exclusive license agreement to practice U.S. Patent Application Serial No. 13/815,829 (anti-body-mediated transduction of heat shock proteins into living cells.). The deal closed on Wednesday, May 13, 2015, and is one of only about 15 direct exclusive license agreements the VA has completed in the past 8 years.
The Kilpatrick Townsend team was led by Kandace Watson, head of Kilpatrick Townsend's Patent and Technology License Practice in the Southwestern United States.
Rubicon Biotechnology is a privately held biotechnology company that develops targeted, life-saving technologies in the areas of defense countermeasures, cardiology, neurology and oncology. Rubicon has in-licensed two platform technologies for drug development. The first is “Antibody Mediated Transduction of Heat Shock Proteins into Living Cells” from the Veterans Administration. This technology delivers heat shock protein, a key protein which saves injured cells that suffer hypoxic and oxidative stresses that occur following unfortunately common tissue injuries, such as heart attack, stroke and traumatic brain injury. The second technology, “Modified Non-Internalizing A5 Variants," licensed from MosaMedix N.V., delivers immunostimulants to tumors in order to enhance the immune system’s ability to fight cancer. With support from several SBIR and CounterACT grants, and in collaboration with major institutions in the U.S., Rubicon is developing these targeted therapies with the goal of improving health outcomes and saving lives.
While we are pleased to have you contact us by telephone, surface mail, electronic mail, or by facsimile transmission, contacting Kilpatrick Townsend & Stockton LLP or any of its attorneys does not create an attorney-client relationship. The formation of an attorney-client relationship requires consideration of multiple factors, including possible conflicts of interest. An attorney-client relationship is formed only when both you and the Firm have agreed to proceed with a defined engagement.
DO NOT CONVEY TO US ANY INFORMATION YOU REGARD AS CONFIDENTIAL UNTIL A FORMAL CLIENT-ATTORNEY RELATIONSHIP HAS BEEN ESTABLISHED.
If you do convey information, you recognize that we may review and disclose the information, and you agree that even if you regard the information as highly confidential and even if it is transmitted in a good faith effort to retain us, such a review does not preclude us from representing another client directly adverse to you, even in a matter where that information could be used against you.